The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study

Autor: Marchal, L., D'Haens, G., van Assche, G., Vermeire, S., Noman, M., Ferrante, M., Hiele, M., Bueno de Mesquita, M., D'Hoore, A., Penninckx, F., Rutgeerts, P.
Přispěvatelé: Other departments
Jazyk: angličtina
Rok vydání: 2004
Zdroj: Alimentary pharmacology & therapeutics, 19(7), 749-754. Wiley-Blackwell
ISSN: 0269-2813
Popis: By temporarily suppressing the immune response, the anti-tumour necrosis factor agent, infliximab, may increase the risk of peri-operative complications. To test this hypothesis for intestinal resection in a cohort of 313 Crohn's disease patients treated with infliximab. Forty received one or more infusions prior to intestinal resection (31/40 within 12 weeks). The post-operative events of these patients were compared with those of a control group (infliximab naive) of 39 patients adjusted for age, gender and surgical procedure. Early (10 days) and late (3 months) major or minor complications were identified. The incidence of early minor (15.0% vs. 12.8%) and major (12.5% vs. 7.7%) and late minor (2.5% vs. 5.1%) and major (17.5% vs. 12.8%) complications and the mean hospital stay after surgery (10.3 +/- 4.0 days vs. 9.9 +/- 5.5 days) were similar in both groups. A trend towards an increased early infection rate was found in infliximab pre-treated patients (6 vs. 1; P = 0.10), but more patients in this group received corticosteroids and/or immunosuppressives (29 vs. 16 patients; P
Databáze: OpenAIRE
Externí odkaz: